<DOC>
	<DOCNO>NCT00224562</DOCNO>
	<brief_summary>The RATIO registry French registry design multidisciplinary group collect data opportunistic severe bacterial infection lymphoma patient treat TNF-a antagonist ( infliximab , etanercept adalimumab ) . A total 486 medical unit metropolitan France participate RATIO registry . All diagnosis retain validation 2 qualify infectious disease haematologist physician ( basis standardize case report form , hospitalisation summary , microbiological radiological result ) . Risk factor develop condition treat TNF-a antagonist identify case control study . Incidence diseases calculate .</brief_summary>
	<brief_title>The RATIO : Registry Infections Lymphoma Patients Treated With TNF-a Antagonists</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Inclusion Criteria case : past current treatement TNFa antagonists either lymphoma severe bacterial infection opportunistic infection Inclusion Criteria control : match case gender , age ( +/ 5 year ) , underlie disease ( rheumatoid arthritis , ankylose spondylitis , Crohn 's disease , psoriasis ) past current treatement TNFa antagonists lymphoma , severe bacterial infection , opportunistic infection ( case )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2004</verification_date>
	<keyword>TNF alpha antagonist</keyword>
	<keyword>infection</keyword>
	<keyword>lymphoma</keyword>
	<keyword>safety</keyword>
</DOC>